BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-based Chemotherapy Response and Prognosis in NSCLC

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 Apr 30

PMID 24779016

Citations 10

Authors

Sun Xian

Lang Jilu

Tian Zhennan

Zhou Yang

Hu Yang

Geng Jingshu

Fu Songbin

Affiliations

Soon will be listed here.

Abstract

To explore the role of genetic polymorphisms of bone morphogenic proteins 4 (BMP-4) in the response to platinum-based chemotherapy and the clinical outcome in patients with advanced nonsmall cell lung cancer (NSCLC), 938 patients with stage III (A+B) or IV NSCLC were enrolled in this study. We found that the variant genotypes of 6007C > T polymorphisms significantly associated with the chemotherapy response. The 6007CC genotype carriers had a higher chance to be responder to chemotherapy (adjusted odd ratio = 2.77; 95% CI: 1.83-4.18; adjusted < 0.001). The 6007C > T polymorphisms and BMP-4 expression also affect the prognosis of NSCLC. Patients with high BMP-4 expression had a significantly higher chance to be resistant to chemotherapy than those with low BMP-4 expression (OR = 2.81; 95% CI: 1.23-6.44; P = 0.01). The hazard ratio (HR) for 6007TT was 2.37 times higher than 6007CC (P = 0.003). In summary, the 6007C > T polymorphism of BMP-4 gene and BMP-4 tissue expression may be used as potential predictor for the chemotherapy response and prognosis of advanced NSCLC.

Citing Articles

Loss of tumor-derived SMAD4 enhances primary tumor growth but not metastasis following BMP4 signalling.

Chi L, Redfern A, Roslan S, Street I, Burrows A, Anderson R Cell Commun Signal. 2024; 22(1):248.

PMID: 38689334 PMC: 11060976. DOI: 10.1186/s12964-024-01559-0.

Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.

Sito H, Tan S Mol Biol Rep. 2024; 51(1):102.

PMID: 38217759 DOI: 10.1007/s11033-023-08915-2.

SOCS3 protein expression predicts the responses of advanced non-small cell lung cancer patients to platinum-based chemotherapy.

Zhang X, Liu T, Li S, Han X, Song R, Wang J Ann Transl Med. 2023; 11(2):94.

PMID: 36819530 PMC: 9929795. DOI: 10.21037/atm-22-6065.

Decreased Thrombospondin-1 and Bone Morphogenetic Protein-4 Serum Levels as Potential Indices of Advanced Stage Lung Cancer.

Kosacka M, Dyla T, Chaszczewska-Markowska M, Bogunia-Kubik K, Brzecka A J Clin Med. 2021; 10(17).

PMID: 34501309 PMC: 8432247. DOI: 10.3390/jcm10173859.

Bioinformatics analysis and verification of molecular targets in ovarian cancer stem-like cells.

Behera A, Ashraf R, Srivastava A, Kumar S Heliyon. 2020; 6(9):e04820.

PMID: 32984578 PMC: 7492822. DOI: 10.1016/j.heliyon.2020.e04820.

References

Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L . Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology. 2010; 140(1):297-309. DOI: 10.1053/j.gastro.2010.10.005. View

Dmitriev A, Kashuba V, Haraldson K, Senchenko V, Pavlova T, Kudryavtseva A . Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays. Epigenetics. 2012; 7(5):502-13. DOI: 10.4161/epi.19801. View

Ivanova T, Zouridis H, Wu Y, Cheng L, Tan I, Gopalakrishnan V . Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut. 2012; 62(1):22-33. DOI: 10.1136/gutjnl-2011-301113. View

Capasso M, Ayala F, Russo R, Avvisati R, Asci R, Iolascon A . A predicted functional single-nucleotide polymorphism of bone morphogenetic protein-4 gene affects mRNA expression and shows a significant association with cutaneous melanoma in Southern Italian population. J Cancer Res Clin Oncol. 2009; 135(12):1799-807. DOI: 10.1007/s00432-009-0628-y. View

Brundage M, Davies D, Mackillop W . Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002; 122(3):1037-57. DOI: 10.1378/chest.122.3.1037. View

Hogan B . Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 1996; 10(13):1580-94. DOI: 10.1101/gad.10.13.1580. View

Ramesh Babu L, Wilson S, Dick I, Islam F, Devine A, Prince R . Bone mass effects of a BMP4 gene polymorphism in postmenopausal women. Bone. 2005; 36(3):555-61. DOI: 10.1016/j.bone.2004.12.005. View

Xu H, Hou X, Wang L, Wang N, Xu J . Association between transforming growth factor beta1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects. Mol Cell Biochem. 2009; 335(1-2):13-7. DOI: 10.1007/s11010-009-0235-x. View

Metro G, Crino L . Novel molecular trends in the management of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2012; 12(6):729-32. DOI: 10.1586/era.12.51. View

10.

Wood N . Cancer: Integrated epigenomic analysis sheds light on role of BMP4 in regulating cisplatin sensitivity in gastric cancer. Nat Rev Gastroenterol Hepatol. 2012; 9(6):301. DOI: 10.1038/nrgastro.2012.95. View

11.

Hou X, Wang L, Wang N, Pang D, Hui B, Zhou Y . The G501C polymorphism of oxidized LDL receptor gene [OLR-1] is associated with susceptibility and serum C-reactive protein concentration in Chinese essential hypertensives. Clin Chim Acta. 2007; 388(1-2):200-3. DOI: 10.1016/j.cca.2007.11.016. View

12.

Hildebrandt M, Gu J, Wu X . Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol. 2009; 5(7):745-55. PMC: 3417337. DOI: 10.1517/17425250902973711. View

13.

Zheng M, Ji Y, Wu X, Ye S, Chen J . EphB4 gene polymorphism and protein expression in non-small-cell lung cancer. Mol Med Rep. 2012; 6(2):405-8. DOI: 10.3892/mmr.2012.936. View

14.

Chang S, Chang T, Peng H, Yeh Y, Lee D, Yeh C . BMP-4 induction of arrest and differentiation of osteoblast-like cells via p21 CIP1 and p27 KIP1 regulation. Mol Endocrinol. 2009; 23(11):1827-38. PMC: 5419157. DOI: 10.1210/me.2009-0143. View

15.

Guo X, Xiong L, Zou L, Zhao J . Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma. Pathol Oncol Res. 2012; 18(3):635-40. DOI: 10.1007/s12253-011-9488-2. View

16.

Tsim S, ODowd C, Milroy R, Davidson S . Staging of non-small cell lung cancer (NSCLC): a review. Respir Med. 2010; 104(12):1767-74. DOI: 10.1016/j.rmed.2010.08.005. View

17.

Li Y, Sun Z, Cunningham J, Aubry M, Wampfler J, Croghan G . Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy. Clin Cancer Res. 2011; 17(11):3830-40. PMC: 3124814. DOI: 10.1158/1078-0432.CCR-10-2877. View

18.

Laatio L, Myllynen P, Serpi R, Rysa J, Ilves M, Lappi-Blanco E . BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells. Tumour Biol. 2011; 32(5):985-95. DOI: 10.1007/s13277-011-0200-7. View

19.

Soini Y, Kahlos K, Puhakka A, Lakari E, Saily M, Paakko P . Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma. Br J Cancer. 2000; 83(7):880-6. PMC: 2374678. DOI: 10.1054/bjoc.2000.1384. View

20.

Wang X, Cui E, Zeng H, Hua F, Wang B, Mao W . RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC. PLoS One. 2012; 7(10):e43734. PMC: 3465300. DOI: 10.1371/journal.pone.0043734. View